Covid booster jabs will begin to be offered across the UK from next week based on JCVI decisions following COVBoost clinical trial data.
PHARMExcel, a U.K. based CRO, is delighted to have been selected as the CRO to support the COVBoost study. Data has contributed to the MHRA approval decisions
PHARMExcel supports recruitment of the first patient into INmuneBio’s pivotal MDS study showing promising results
Initial covboost study data ready for analysis..
PHARMExcel running MDS trial that sees first patient treated
Covid: Bradford NHS consultant first in world to receive booster vaccine
UK records zero Covid daily deaths as scientists warn of third wave
PHARMExcel to support trial delivery of world-first Covid-19 vaccine booster study.
PHARMExcel is delighted to be announced as the UK Contract Research Organisation (CRO) supporting University Hospital Southampton in the delivery of a world-first Covid-19 vaccine booster study. The Cov-Boost study, backed by £19.3 million of government funding through the Vaccines Taskforce, will be run at University Hospital Southampton, University Hospitals Dorset and the Portsmouth Research…